22nd June 2020 Content supplied by: ChromaCode
ChromaCode's High-definition COVID-19 qPCR test is now FDA-EUA
ChromaCode, Inc., has been granted EUA by the U.S. Food and Drug Administration for its HDPCR™ SARS-CoV-2 Real-Time PCR Assay. The assay was launched in April after validation by ChromaCode, in line with the FDA's EUA regulations.
The HDPCR™ SARS-CoV-2 Real-Time PCR Assay is intended to detect severe acute respiratory syndrome coronavirus 2 from nasopharyngeal swab specimens from patients suspected by their healthcare provider of having contracted COVID-19. Later this year, ChromaCode intends to leverage its unique multiplexing technology to launch a COVID assay that combines multiple respiratory viruses into a single test in anticipation of the upcoming flu season.
In addition to ChromaCode's inventory guarantee, the company's HDPCR™ SARS-CoV-2 Real-Time PCR Assay:
- Enables frictionless adoption by running on standard qPCR instruments — including the Applied Biosystems™️ 7500 Fast, QuantStudio™️ 7 and QuantStudio™️ 12K — with no hardware/software changes required. Onsite training is not required as training is performed via a web-based application.
- Makes throughput scalable by consolidating the CDC assay into a single reaction well so labs can run 1,000+ samples per qPCR instrument over a 24/7 testing period.
- Streamlines data analysis and result management through the company's intuitive and user-friendly software platform, ChromaCode Cloud.
- Ensures full security and data privacy with HIPAA compliant cloud software that does not store protected health information (PHI).
ChromaCode's platform is built on the use of data science technology — including proprietary signal processing techniques — and cloud-computing algorithms to boost the performance of commonly used molecular diagnostics instruments and reagents, setting ChromaCode apart from legacy diagnostics companies.
HDPCR expands the number of detectable disease targets in a single reaction using traditional qPCR or dPCR instruments, without any changes to workflow, instrumentation or software. ChromaCode's data-driven approach enhances the performance of traditional diagnostics hardware by as much as 5x, saving time and money on testing that is critical to patient care.
Learn more about ChromaCode's HDPCR™ SARS-CoV-2 Real-Time PCR Assay by visiting https://chromacode.com/products/hdpcr-sars-cov-2-assay/#/sars-cov-2.
Date Published: 22nd June 2020
Source article link: View